Postmenopausal women with osteoporosis: experience when treated with teriparatide in clinical practice

被引:4
|
作者
Ish-Shalom, Sophia [1 ]
Dumitrache, Constantin [2 ]
El-Husseini, Timour Fikry [3 ]
Hussein, Azza [4 ]
Barker, Clare [5 ]
Pavo, Imre [6 ]
机构
[1] Technion Fac Med, Bone & Mineral Metab Unit, Haifa, Israel
[2] CI Parhon Inst Endocrinol, Bucharest, Romania
[3] Ain Shams Univ, Fac Med, Dept Orthoped Surg, Cairo, Egypt
[4] Ain Shams Univ, Fac Med, Dept Rheumatol, Cairo, Egypt
[5] Lilly Res Labs UK, Surrey, England
[6] Lilly Reg Operat Vienna, Dept Med, Vienna, Austria
关键词
QUALITY-OF-LIFE; RADIOGRAPHIC VERTEBRAL FRACTURE; BONE-MINERAL DENSITY; BACK-PAIN; PARATHYROID-HORMONE; OLDER WOMEN; DISABILITY; DEFORMITIES; PREVALENT; RISK;
D O I
10.1185/03007995.2010.540007
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
To observe and compare back pain and health-related quality of life (HRQoL) in postmenopausal women with a prior unsatisfactory response to antiresorptive therapy, treated with teriparatide (TPTD) or alternative treatments in normal clinical practice. Prospective, observational, multicentre, 24-month study of postmenopausal women with osteoporosis. A back pain and HRQoL questionnaire (European Quality of Life Questionnaire, EQ-5D) including visual analogue scale (VAS) was completed at each visit. A total of 153 patients were enrolled, 105 patients started TPTD treatment during the study (TPTD cohort) and 48 patients did not take TPTD treatment at any time during the study (non-TPTD cohort). Four patients did not meet the inclusion criteria for the study. Of the patients in the non-TPTD cohort, 31 (68.9%) took antiresorptives during the study. The patients selected by the investigator for teriparatide treatment were distinctly different from those not selected. At baseline, the mean back pain VAS was greater in the TPTD than the non-TPTD cohort, 64 mm and 42 mm, respectively (p < 0.001). During the study, compared with baseline, the mean back pain VAS decreased in the TPTD cohort at all visits (p < 0.001). In the non-TPTD cohort, a transitory decrease in the mean after 12 months was observed (-10 mm, p = 0.023) only. After 24 months, the mean back pain VAS improved in the TPTD cohort (-36 mm, p < 0.001) while no change was observed in the non-TPTD cohort (-4 mm, p = 0.467). At baseline, the mean EQ-VAS was lower in the TPTD than in the non-TPTD cohort, 40.8 and 55.2, respectively (p < 0.001). After 24 months, EQ-VAS improved in both cohorts (TPTD 34, p < 0.001 and non-TPTD 9, p = 0.026). TPTD-treated patients had more back pain and lower HRQoL at baseline. In the TPTD cohort the mean value was consistently and significantly improved in back pain and quality of life. In the non-TPTD cohort, the mean improvement in back pain and QoL was inconsistent possibly due to the initially higher QoL and lower back pain leaving less room for improvement. These results should be interpreted in the context of limitations related to a non-randomised observational study.
引用
收藏
页码:343 / 353
页数:11
相关论文
共 50 条
  • [1] Bone marker variations in postmenopausal women with osteoporosis treated with teriparatide
    Barata, S.
    Osorio, F.
    Pauleta, J.
    Santo, S.
    Neves, J.
    Pereira-Coelho, A.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2006, 17 : S342 - S342
  • [2] COMPARING CLINICAL AND ECONOMIC OUTCOMES OF DENOSUMAB AND TERIPARATIDE MEDICATIONS IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS 10 YEARS EXPERIENCE
    Zidan, S. F. Z.
    Elsalmawy, A. H. E.
    Bajuifer, S. J. B.
    Almaimani, W. H. A.
    [J]. AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2022, 34 (SUPPL 1) : S108 - S109
  • [3] Efficacy of adding teriparatide versus switching to teriparatide in postmenopausal women with osteoporosis previously treated with raloxifene or alendronate
    Cosman, F.
    Wermers, R. A.
    Recknor, C.
    Mauck, K. F.
    Xie, L.
    Glass, E. V.
    Krege, J. H.
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2007, 22 : S127 - S127
  • [4] Efficacy of adding teriparatide versus switching to teriparatide in postmenopausal women with osteoporosis previously treated with raloxifene or alendronate
    Cosman, F.
    Wermers, R. A.
    Recknor, C.
    Mauck, K. F.
    Xie, L.
    Glass, E. V.
    Krege, J. H.
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2007, 22 : S89 - S89
  • [5] Efficacy of adding teriparatide versus switching to teriparatide in postmenopausal women with osteoporosis previously treated with raloxifene or alendronate
    Cosman, F.
    Wermers, R. A.
    Recknor, C.
    Mauck, K. F.
    Xie, L.
    Glass, E. V.
    Krege, J. H.
    [J]. CALCIFIED TISSUE INTERNATIONAL, 2008, 82 : S59 - S60
  • [6] Relationship between duration of teriparatide therapy and clinical outcomes in postmenopausal women with osteoporosis
    R. Lindsay
    P. Miller
    G. Pohl
    E. V. Glass
    P. Chen
    J. H. Krege
    [J]. Osteoporosis International, 2009, 20 : 943 - 948
  • [7] Relationship between duration of teriparatide therapy and clinical outcomes in postmenopausal women with osteoporosis
    Lindsay, R.
    Miller, P.
    Pohl, G.
    Glass, E. V.
    Chen, P.
    Krege, J. H.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2009, 20 (06) : 943 - 948
  • [8] COMPARING CLINICAL AND ECONOMIC OUTCOMES OF DENOSUMAB AND TERIPARATIDE MEDICATIONS IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS
    Elsalmawy, A. H. E.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2018, 29 : S219 - S219
  • [9] Effects of teriparatide on serum calcium in postmenopausal women with osteoporosis previously treated with raloxifene or alendronate
    R. A. Wermers
    C. P. Recknor
    F. Cosman
    L. Xie
    E. V. Glass
    J. H. Krege
    [J]. Osteoporosis International, 2008, 19 : 1055 - 1065
  • [10] Vertebral and Femoral Strength Increased In Postmenopausal Women with Osteoporosis Treated with Teriparatide for 18 Months
    Keaveny, Tony M.
    Maricic, Michael
    Kopperdahl, David
    Ruff, Valerie
    Wan, Xiaohai
    Krohn, Kelly
    [J]. ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S429 - S429